litlas
Log inCreate account

Edith A. Perez

Active 1988–2024

Also published as
EDITH A. PEREZ
156
Papers
60,527
Citations
104
h-index
156
i10-index

Citations

Citations per year for Edith A. Perez1971: 3 citations1974: 2 citations1981: 2 citations1984: 1 citations1988: 1 citations1992: 2 citations1993: 1 citations1995: 2 citations1997: 2 citations1998: 3 citations1999: 6 citations2000: 16 citations2001: 8 citations2002: 32 citations2003: 53 citations2004: 75 citations2005: 124 citations2006: 203 citations2007: 341 citations2008: 494 citations2009: 568 citations2010: 610 citations2011: 608 citations2012: 582 citations2013: 603 citations2014: 524 citations2015: 615 citations2016: 650 citations2017: 578 citations2018: 498 citations2019: 1,571 citations2020: 1,548 citations2021: 1,326 citations2022: 1,015 citations2023: 706 citations2024: 1,037 citations2025: 414 citations2026: 12 citations1972–1973: no citations, so these years are not shown1975–1980: no citations, so these years are not shown1982–1983: no citations, so these years are not shown1985–1987: no citations, so these years are not shown1989–1991: no citations, so these years are not shown1994: no citations, so this year is not shown1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,093 citing papers, 26.8% of this breakdownChina: 1,471 citing papers, 7.7% of this breakdownUnited Kingdom: 1,107 citing papers, 5.8% of this breakdownItaly: 1,073 citing papers, 5.6% of this breakdownGermany: 829 citing papers, 4.4% of this breakdownCanada: 770 citing papers, 4% of this breakdownFrance: 759 citing papers, 4% of this breakdownSpain: 625 citing papers, 3.3% of this breakdownBelgium: 551 citing papers, 2.9% of this breakdownSwitzerland: 544 citing papers, 2.9% of this breakdownAustralia: 539 citing papers, 2.8% of this breakdownJapan: 516 citing papers, 2.7% of this breakdown
0%26.8%Other 27.1%

Institutions

Fields

  • Medicine56.3%
  • Biochemistry, Genetics and Molecular Biology33.4%
  • Computer Science2.4%
  • Immunology and Microbiology2.2%
  • Materials Science1.1%
  • Pharmacology, Toxicology and Pharmaceutics1.1%
  • Other3.5%

Topics

  • Breast Cancer Treatment Studies9%
  • HER2/EGFR in Cancer Research8.4%
  • Cancer Immunotherapy and Biomarkers4.1%
  • Cancer Treatment and Pharmacology4%
  • Advanced Breast Cancer Therapies3.4%
  • Monoclonal and Polyclonal Antibodies Research2.6%
  • Other68.5%

Coauthors

All papers

Open in search
  1. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    Authors: Roberto Salgado, Carsten Denkert, Sandra Demaria, Nicolas Sirtaine, Frederick Klauschen, Giancarlo Pruneri, Stephan Wienert, Gert Van den Eynden, Frederick L. Baehner, Frédérique Penault‐Llorca, Edith A. Perez, E. Aubrey Thompson, W. Fraser Symmans, Andrea L. Richardson, Jane Brock, Carmen Criscitiello, Helen D. Bailey, M. Ignatiadis, Giuseppe Floris, Joseph A. Sparano, Zuzana Kos, Torsten O. Nielsen, David L. Rimm, Kimberly H. Allison, Jorge S. Reis‐Filho, Sibylle Loibl, Christos Sotiriou, Giuseppe Viale, Sunil Badve, Sylvia Adams, Karen Willard‐Gallo, Sherene Loi - Annals of Oncology 2014 cited by 3,136

  2. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

    Authors: Kevin Kalinsky, William E. Barlow, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Stephen K.L. Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martin, Catherine M. Kelly, Manuel Ruiz-Borrego, Miguel Gil-Gil, Claudia H. Arce-Salinas, Etienne G.C. Brain, Eun-Sook Lee, Jean-Yves Pierga, Begoña Bermejo, Manuel Ramos-Vazquez, Kyung-Hae Jung, Jean-Marc Ferrero, Anne F. Schott, Steven Shak, Priyanka Sharma, Danika L. Lew, Jieling Miao, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi - New England Journal of Medicine 2021 cited by 832

  3. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

    Authors: Edward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela Klein, James N. Ingle, Norman Wolmark - New England Journal of Medicine 2005 cited by 5,353

  4. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

    Authors: Sylvia Adams, Robert J. Gray, Sandra Demaria, Lori J. Goldstein, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Molin Wang, Vicky Jones, Thomas J. Saphner, Antonio C. Wolff, William C. Wood, Nancy E. Davidson, George W. Sledge, Joseph A. Sparano, Sunil Badve - Journal of Clinical Oncology 2014 cited by 1,333

  5. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

    Authors: Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks, Mitch Dowsett, Lisa M. McShane, Kimberly H. Allison, D. Craig Allred, John M.S. Bartlett, Michael Bilous, Patrick L. Fitzgibbons, Wedad Hanna, Robert B. Jenkins, Pamela B. Mangu, Soonmyung Paik, Edith A. Perez, Michael F. Press, Patricia A. Spears, Gail H. Vance, Giuseppe Viale, Daniel F. Hayes - Archives of Pathology & Laboratory Medicine 2013 cited by 4,061

  6. Treatment of HER2-positive breast cancer: current status and future perspectives

    Authors: Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni - Nature Reviews Clinical Oncology 2011 cited by 871

  7. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, John A. Olson, JoAnne Zujewski, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, James N. Atkins, Jeffrey L. Berenberg, George W. Sledge - New England Journal of Medicine 2015 cited by 1,439

  8. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

    Authors: Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, Karen L. Hagerty, D. Craig Allred, Richard J. Côté, Mitch Dowsett, Patrick L. Fitzgibbons, Wedad Hanna, Amy S. Langer, Lisa M. McShane, Soonmyung Paik, Mark D. Pegram, Edith A. Perez, Michael F. Press, Anthony Rhodes, Catharine M. Sturgeon, Sheila E. Taube, Raymond Tubbs, Gail H. Vance, Marc J. van de Vijver, Thomas M. Wheeler, Daniel F. Hayes - Archives of Pathology & Laboratory Medicine 2006 cited by 4,475

  9. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    Authors: Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, S Stanzel, Alexander Strasak, Monika Patre, Paul Ellis - Journal of Clinical Oncology 2017 cited by 413

  10. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Authors: Olivia Pagani, Meredith M. Regan, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Edith A. Perez, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Graziella Pinotti, Fabio Puglisi, Diana Crivellari, Thomas Ruhstaller, Eric P. Winer, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Anita Giobbie‐Hurder, Karen N. Price, Jürg Bernhard, Weixiu Luo, Karin Ribi, Giuseppe Viale, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Prudence A. Francis - New England Journal of Medicine 2014 cited by 747

  11. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

    Authors: Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, George W. Sledge, Charles E. Geyer, Silvana Martino, Priya Rastogi, Julie R. Gralow, Sandra M. Swain, Eric P. Winer, Gerardo Colón‐Otero, Nancy E. Davidson, E. Mamounas, Jo Anne Zujewski, Norman Wolmark - Journal of Clinical Oncology 2014 cited by 998

  12. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

    Authors: Joseph A. Sparano, Molin Wang, Silvana Martino, Vicky Jones, Edith A. Perez, Tom Saphner, Antonio C. Wolff, George W. Sledge, William C. Wood, Nancy E. Davidson - New England Journal of Medicine 2008 cited by 1,029

  13. A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.

    Authors: Bob T. Li, Mark D. Pegram, Keun‐Wook Lee, Manish Sharma, Jeeyun Lee, Alexander I. Spira, Glenn J. Hanna, Yoon‐Koo Kang, Drew Rasco, Kathleen N. Moore, Benjamin A. Weinberg, Michael N. Alonso, Jason Ptacek, Ming Yin, Coya Tapia, Lu Xu, Edith A. Perez, Ecaterina E. Dumbrava - Journal of Clinical Oncology 2023 cited by 46

  14. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

    Authors: Kathy D. Miller, Molin Wang, Julie R. Gralow, Maura N. Dickler, Melody Cobleigh, Edith A. Perez, Tamara Shenkier, David Cella, Nancy E. Davidson - New England Journal of Medicine 2007 cited by 3,053

  15. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Authors: Marc L. Citron, Donald A. Berry, Constance Cirrincione, Clifford A. Hudis, Eric P. Winer, William J. Gradishar, Nancy E. Davidson, Silvana Martino, Robert B. Livingston, James N. Ingle, Edith A. Perez, John T. Carpenter, David D. Hurd, James F. Holland, Barbara L. Smith, Carolyn I. Sartor, Eleanor H. Leung, Jeffrey S. Abrams, Richard L. Schilsky, Hyman B. Muss, Larry Norton - Journal of Clinical Oncology 2003 cited by 1,564

  16. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Authors: Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Chan, Xian Zhou, S. Phan, Joyce O’Shaughnessy - Journal of Clinical Oncology 2011 cited by 1,061

  17. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Authors: Kathy S. Albain, William E. Barlow, Steven Shak, Gabriel N. Hortobágyi, Robert B. Livingston, I‐Tien Yeh, Peter M. Ravdin, Roberto Bugarini, Frederick L. Baehner, Nancy E. Davidson, George W. Sledge, Eric P. Winer, Clifford A. Hudis, James N. Ingle, Edith A. Perez, Kathleen I. Pritchard, Lois E. Shepherd, Julie R. Gralow, Carl Yoshizawa, D. Craig Allred, C. Kent Osborne, Daniel F. Hayes - The Lancet Oncology 2009 cited by 1,405

  18. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

    Authors: Evandro de Azambuja, Andrew Holmes, Martine Piccart, Eileen Holmes, Serena Di Cosimo, Ramona F. Swaby, Michael Untch, Christian Jackisch, István Láng, Ian Smith, Frances Boyle, Binghe Xu, Carlos H. Barrios, Edith A. Perez, Hatem A. Azim, Sung‐Bae Kim, Sherko Küemmel, Chiun‐Sheng Huang, Peter Vuylsteke, Ruey‐Kuen Hsieh, В. А. Горбунова, Alexandru Eniu, Lydia Dreosti, Natalia Tavartkiladze, Richard D. Gelber, Holger Eidtmann, José Baselga - The Lancet Oncology 2014 cited by 455

  19. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

    Authors: Ian E. Krop, Ingrid A. Mayer, Vinod Ganju, Maura N. Dickler, Stephen Johnston, Serafín Morales, Denise A. Yardley, Bohuslav Melichar, Andres Forero‐Torres, Soo Chin Lee, Richard de Boer, Katarína Petráková, Susanne Vallentin, Edith A. Perez, Martine Piccart, Matthew J. Ellis, Eric P. Winer, Steven Gendreau, Mika K. Derynck, Mark R. Lackner, Gallia G. Levy, Jiaheng Qiu, Jing He, Peter Schmid - The Lancet Oncology 2016 cited by 295

  20. Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

    Authors: Sara A. Hurvitz, Luc Dirix, Judit Kocsis, Giulia Bianchi, Janice Lu, J. Vinholes, Ellie Guardino, Chunyan Song, Barbara Tong, Vivian Ng, Yu-Waye Chu, Edith A. Perez - Journal of Clinical Oncology 2013 cited by 391

  21. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

    Authors: Lawrence J. Solin, Robert P. Gray, Frederick L. Baehner, Steven M. Butler, Lorie L. Hughes, Carl Yoshizawa, Diana B. Cherbavaz, S. Shak, David L. Page, G. W. Sledge, Nancy E. Davidson, J. N. Ingle, Edith A. Perez, W. C. Wood, Joseph A. Sparano, S Badve - JNCI Journal of the National Cancer Institute 2013 cited by 523

  22. Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Authors: Peter A. Kaufman, Ahmad Awada, Chris Twelves, Louise Yelle, Edith A. Perez, Galina Velikova, Martin Olivo, Yi He, Corina E. Dutcus, Javier Cortés - Journal of Clinical Oncology 2015 cited by 464

  23. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

    Authors: Joseph A. Sparano, Fengmin Zhao, Silvana Martino, Jennifer A. Ligibel, Edith A. Perez, Tom Saphner, Antonio C. Wolff, George W. Sledge, William C. Wood, Nancy E. Davidson - Journal of Clinical Oncology 2015 cited by 223

  24. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

    Authors: Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, Sanne de Haas, Silke Hoersch, Monika Patre, Paul Anthony Ellis - Cancer 2019 cited by 114